Compagnie Lombard Odier SCmA’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $425K | Buy |
550
+100
| +22% | +$76.6K | 0.01% | 208 |
|
|
2025
Q4 | $347K | Hold |
450
| – | – | ﹤0.01% | 217 |
|
|
2025
Q3 | $253K | Hold |
450
| – | – | ﹤0.01% | 238 |
|
|
2025
Q2 | $236K | Hold |
450
| – | – | ﹤0.01% | 230 |
|
|
2025
Q1 | $285K | Hold |
450
| – | – | ﹤0.01% | 231 |
|
|
2024
Q4 | $321K | Hold |
450
| – | – | ﹤0.01% | 208 |
|
|
2024
Q3 | $473K | Hold |
450
| – | – | 0.01% | 184 |
|
|
2024
Q2 | $473K | Sell |
450
-195
| -30% | -$189K | 0.01% | 184 |
|
|
2024
Q1 | $621K | Sell |
645
-45
| -7% | -$42.8K | 0.01% | 181 |
|
|
2023
Q4 | $606K | Hold |
690
| – | – | 0.01% | 202 |
|
|
2023
Q3 | $568K | Sell |
690
-1,090
| -61% | -$857K | 0.01% | 178 |
|
|
2023
Q2 | $1.28M | Hold |
1,780
| – | – | 0.04% | 131 |
|
|
2023
Q1 | $1.46M | Sell |
1,780
-100
| -5% | -$75.4K | 0.04% | 142 |
|
|
2022
Q4 | $1.36M | Hold |
1,880
| – | – | 0.04% | 142 |
|
|
2022
Q3 | $1.29M | Hold |
1,880
| – | – | 0.04% | 148 |
|
|
2022
Q2 | $1.11M | Hold |
1,880
| – | – | 0.03% | 149 |
|
|
2022
Q1 | $1.31M | Hold |
1,880
| – | – | 0.03% | 141 |
|
|
2021
Q4 | $1.19M | Hold |
1,880
| – | – | 0.02% | 165 |
|
|
2021
Q3 | $1.14M | Buy |
1,880
+810
| +76% | +$503K | 0.02% | 168 |
|
|
2021
Q2 | $598K | Sell |
1,070
-105
| -9% | -$53.2K | 0.01% | 207 |
|
|
2021
Q1 | $556K | Sell |
1,175
-175
| -13% | -$85.2K | 0.01% | 262 |
|
|
2020
Q4 | $652K | Buy |
1,350
+80
| +6% | +$43.2K | 0.02% | 199 |
|
|
2020
Q3 | $711K | Buy |
1,270
+280
| +28% | +$170K | 0.02% | 171 |
|
|
2020
Q2 | $617K | Sell |
990
-190
| -16% | -$108K | 0.02% | 175 |
|
|
2020
Q1 | $576K | Buy |
1,180
+380
| +48% | +$157K | 0.02% | 167 |
|
|
2019
Q4 | $300K | Sell |
800
-101
| -11% | -$34K | 0.01% | 222 |
|
|
2019
Q3 | $250K | Hold |
901
| – | – | 0.01% | 230 |
|
|
2019
Q2 | $282K | Sell |
901
-277
| -24% | -$92.2K | 0.01% | 221 |
|
|
2019
Q1 | $483K | Sell |
1,178
-300
| -20% | -$124K | 0.02% | 199 |
|
|
2018
Q4 | $552K | Buy |
1,478
+78
| +6% | +$28.5K | 0.02% | 191 |
|
|
2018
Q3 | $566K | Hold |
1,400
| – | – | 0.02% | 195 |
|
|
2018
Q2 | $483K | Sell |
1,400
-60
| -4% | -$18.8K | 0.02% | 210 |
|
|
2018
Q1 | $503K | Sell |
1,460
-1,526
| -51% | -$531K | 0.02% | 221 |
|
|
2017
Q4 | $1.12M | Buy |
+2,986
| New | +$1.21M | 0.02% | 225 |
|
|
2017
Q2 | – | Sell |
-70
| Closed | -$27K | – | 750 |
|
|
2017
Q1 | $27K | Buy |
+70
| New | +$25.9K | ﹤0.01% | 600 |
|
|
2015
Q2 | – | Sell |
-216
| Closed | -$98K | – | 912 |
|
|
2015
Q1 | $98K | Hold |
216
| – | – | ﹤0.01% | 663 |
|
|
2014
Q4 | $89K | Sell |
216
-487
| -69% | -$192K | ﹤0.01% | 560 |
|
|
2014
Q3 | $254K | Sell |
703
-229
| -25% | -$76.8K | 0.01% | 450 |
|
|
2014
Q2 | $263K | Hold |
932
| – | – | 0.01% | 468 |
|
|
2014
Q1 | $280K | Buy |
932
+393
| +73% | +$121K | 0.01% | 440 |
|
|
2013
Q4 | $148K | Buy |
+539
| New | +$155K | 0.01% | 587 |
|
Other funds holding REGN
VCM
N
Compagnie Lombard Odier SCmA's REGN Position: Q1 2026 in Review
Compagnie Lombard Odier SCmA increased its Regeneron Pharmaceuticals (REGN) stake by 22% in Q1 2026, buying an estimated $76.6K and bringing the position to 550 shares worth $425K. The position accounts for 0.01% of the portfolio, ranked #208.
Compagnie Lombard Odier SCmA first reported a position in REGN in Q4 2013 and has held it in 41 quarters since. The position peaked at $1.46M in Q1 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Compagnie Lombard Odier SCmA held 550 shares of Regeneron Pharmaceuticals worth $425K as of Q1 2026.
- Compagnie Lombard Odier SCmA bought 100 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $76.6K.
- Regeneron Pharmaceuticals made up 0.01% of Compagnie Lombard Odier SCmA's portfolio in Q1 2026, its #208 holding.
- Compagnie Lombard Odier SCmA first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 41 quarters since.
- Compagnie Lombard Odier SCmA's Regeneron Pharmaceuticals position peaked at $1.46M in Q1 2023.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2026, filed 15 Apr 2026.